Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Generics Maker Watson To Buy Rival Actavis
by Michael McCoy
April 30, 2012
| A version of this story appeared in
Volume 90, Issue 18
The generic drug maker Watson Pharmaceuticals has agreed to acquire its rival Actavis for about $5.6 billion. Watson says the purchase will create the world’s third-largest generics company after Teva Pharmaceutical Industries and Sandoz. Watson’s generics sales last year were $3.4 billion; Actavis’ were $2.3 billion. The overall sales of the two firms this year are expected to reach $8.0 billion. Watson CEO Paul M. Bisaro says the purchase of the Icelandic firm will substantially boost Watson’s international presence. He also anticipates savings of more than $300 million from the combination.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter